China Universal Asset Management Co. Ltd. boosted its position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) by 63.1% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 36,991 shares of the biotechnology company's stock after purchasing an additional 14,310 shares during the period. China Universal Asset Management Co. Ltd.'s holdings in BioMarin Pharmaceutical were worth $2,600,000 at the end of the most recent quarter.
A number of other large investors have also recently bought and sold shares of the business. Envestnet Portfolio Solutions Inc. grew its position in shares of BioMarin Pharmaceutical by 1.2% during the 1st quarter. Envestnet Portfolio Solutions Inc. now owns 10,668 shares of the biotechnology company's stock worth $932,000 after buying an additional 130 shares during the period. Quent Capital LLC increased its position in shares of BioMarin Pharmaceutical by 58.9% during the second quarter. Quent Capital LLC now owns 391 shares of the biotechnology company's stock worth $32,000 after acquiring an additional 145 shares in the last quarter. SteelPeak Wealth LLC raised its holdings in shares of BioMarin Pharmaceutical by 10.9% in the 1st quarter. SteelPeak Wealth LLC now owns 2,498 shares of the biotechnology company's stock worth $218,000 after acquiring an additional 246 shares during the last quarter. Grandfield & Dodd LLC boosted its stake in BioMarin Pharmaceutical by 1.6% during the 1st quarter. Grandfield & Dodd LLC now owns 16,127 shares of the biotechnology company's stock valued at $1,409,000 after purchasing an additional 255 shares during the last quarter. Finally, AIA Group Ltd boosted its position in shares of BioMarin Pharmaceutical by 7.0% during the first quarter. AIA Group Ltd now owns 4,076 shares of the biotechnology company's stock valued at $356,000 after buying an additional 266 shares during the last quarter. 98.71% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
A number of analysts recently commented on BMRN shares. Evercore ISI lifted their price target on BioMarin Pharmaceutical from $113.00 to $115.00 and gave the stock an "outperform" rating in a report on Tuesday, August 6th. William Blair upgraded shares of BioMarin Pharmaceutical to a "strong-buy" rating in a research note on Friday, August 30th. Canaccord Genuity Group restated a "hold" rating and set a $93.00 price target on shares of BioMarin Pharmaceutical in a research note on Friday, September 13th. StockNews.com raised BioMarin Pharmaceutical from a "hold" rating to a "buy" rating in a research report on Thursday, August 8th. Finally, Barclays decreased their price objective on BioMarin Pharmaceutical from $110.00 to $86.00 and set an "overweight" rating for the company in a report on Friday, October 4th. Seven equities research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $96.40.
Check Out Our Latest Stock Analysis on BioMarin Pharmaceutical
BioMarin Pharmaceutical Stock Performance
NASDAQ:BMRN traded down $0.22 during mid-day trading on Tuesday, reaching $69.91. The company's stock had a trading volume of 1,826,411 shares, compared to its average volume of 1,844,403. The stock has a market cap of $13.27 billion, a P/E ratio of 65.54, a PEG ratio of 0.81 and a beta of 0.31. The company has a current ratio of 3.05, a quick ratio of 1.95 and a debt-to-equity ratio of 0.11. BioMarin Pharmaceutical Inc. has a 12-month low of $67.75 and a 12-month high of $99.56. The firm's fifty day moving average price is $77.08 and its two-hundred day moving average price is $81.20.
BioMarin Pharmaceutical (NASDAQ:BMRN - Get Free Report) last released its quarterly earnings data on Monday, August 5th. The biotechnology company reported $0.77 earnings per share for the quarter, topping analysts' consensus estimates of $0.38 by $0.39. BioMarin Pharmaceutical had a return on equity of 6.91% and a net margin of 9.91%. The firm had revenue of $712.03 million during the quarter, compared to analyst estimates of $660.51 million. On average, equities analysts forecast that BioMarin Pharmaceutical Inc. will post 2.39 EPS for the current fiscal year.
BioMarin Pharmaceutical Profile
(
Free Report)
BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.
Featured Stories
Before you consider BioMarin Pharmaceutical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioMarin Pharmaceutical wasn't on the list.
While BioMarin Pharmaceutical currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
